Biomarker and Druggable Target of Neurodegeneration
AssigneeUniversity Hospitals Cleveland Medical Center
InventorsAndrew A. Pieper, Min-Kyoo Shin, Edwin Vazquez-Rosa
Life of this patent
Estimating the term…
Abstract
In one aspect, disclosed herein is a method of diagnosing and/or prognosing a neurodegenerative disease in a subject, the method comprising: obtaining a plasma or blood sample from a subject; and detecting a level of acetylated Tau in the plasma or blood sample, wherein a level of acetylated Tau that is at least 25% or 50% higher than a control level in a healthy subject indicates that the subject has a neurodegenerative disease such as traumatic brain injury.
Claims20
A method of diagnosing and/or prognosing a neurodegenerative disease in a subject, the method comprising:
- obtaining a plasma or blood sample from a subject;
- and
- detecting a level of acetylated tau in the plasma or blood sample, wherein a level of acetylated tau that is at least 25% or 50% higher than a control level in a healthy subject indicates that the subject has a neurodegenerative disease such as traumatic brain injury.
A method of treating a neurodegenerative disease in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of an agent that blocks GAPDH S-nitrosylation, inhibits p300/CBP activity, and/or enhances Sirtuin1 activity, whereby accumulation of ac-tau in brain and/or plasma in the subject is reduced.
An apparatus for diagnosing and/or prognosing a neurodegenerative disease in a subject, comprising:
- a support material;
- and
- an antibody or antigen-binding fragment thereof that specifically binds acetylated tau, wherein said antibody or antigen-binding fragment thereof is adsorbed in or associated with the support material.
Dependencies are inferred from the claim text.